9b2b
From Proteopedia
(Difference between revisions)
												
			
			| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Complete Estrogen Receptor Antagonists that Favors Tetramer Formation== | |
| - | + | <StructureSection load='9b2b' size='340' side='right'caption='[[9b2b]], [[Resolution|resolution]] 2.08Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[9b2b]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9B2B OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9B2B FirstGlance]. <br> | |
| - | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.08Å</td></tr> | |
| - | [[Category:  | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1AI0:2-chloro-3-{[{[1-(2-fluorophenyl)cyclopentyl]methyl}(4-{[1-(3-fluoropropyl)azetidin-3-yl]oxy}phenyl)amino]methyl}phenol'>A1AI0</scene></td></tr> | 
| - | [[Category:  | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9b2b FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9b2b OCA], [https://pdbe.org/9b2b PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9b2b RCSB], [https://www.ebi.ac.uk/pdbsum/9b2b PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9b2b ProSAT]</span></td></tr> | 
| - | [[Category: Chawla | + | </table> | 
| - | [[Category:  | + | == Function == | 
| - | [[Category:  | + | [https://www.uniprot.org/uniprot/ESR1_HUMAN ESR1_HUMAN] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.<ref>PMID:7651415</ref> <ref>PMID:10970861</ref> <ref>PMID:9328340</ref> <ref>PMID:10681512</ref> <ref>PMID:10816575</ref> <ref>PMID:11477071</ref> <ref>PMID:11682626</ref> <ref>PMID:15078875</ref> <ref>PMID:16043358</ref> <ref>PMID:15891768</ref> <ref>PMID:16684779</ref> <ref>PMID:18247370</ref> <ref>PMID:17932106</ref> <ref>PMID:19350539</ref> <ref>PMID:20705611</ref> <ref>PMID:21937726</ref> <ref>PMID:21330404</ref> <ref>PMID:22083956</ref>  | 
| - | [[Category:  | + | == References == | 
| - | [[Category:  | + | <references/> | 
| - | [[Category:  | + | __TOC__ | 
| - | [[Category:  | + | </StructureSection> | 
| - | [[Category: Wells | + | [[Category: Homo sapiens]] | 
| + | [[Category: Large Structures]] | ||
| + | [[Category: Barratt S]] | ||
| + | [[Category: Chawla R]] | ||
| + | [[Category: Fanning SW]] | ||
| + | [[Category: Fink EC]] | ||
| + | [[Category: Myles DC]] | ||
| + | [[Category: Ng R]] | ||
| + | [[Category: Pena G]] | ||
| + | [[Category: Robello BW]] | ||
| + | [[Category: Wells KS]] | ||
Current revision
Estrogen Receptor Alpha Ligand Binding Domain in Complex with a Complete Estrogen Receptor Antagonists that Favors Tetramer Formation
| 
 | |||||||||||
Categories: Homo sapiens | Large Structures | Barratt S | Chawla R | Fanning SW | Fink EC | Myles DC | Ng R | Pena G | Robello BW | Wells KS
